Recent developments include the launch of a large-scale lung cancer clinical study, ongoing research collaborations, and mixed stock price reactions to quarterly earnings reflecting revenue and loss trends.

• In March 2026, bioAffinity enrolled the first patient in a large-scale clinical trial to evaluate CyPath® Lung's performance in detecting early-stage lung cancer in high-risk patients with indeterminate pulmonary nodules [N2].
• The company announced continued research collaborations with military medical centers to validate and expand the use of CyPath® Lung and develop companion diagnostics for asthma and COPD [N2].
• In May 2026, the company reported Q1 earnings with strength in CyPath Lung sales but stock price slipped post-earnings [N1].
• In November 2025, the stock dipped following Q3 earnings reflecting lower sales and wider losses [N3].
• In August 2025, the stock declined after Q2 earnings despite growth in CyPath Lung test sales, with the company missing Q2 revenue targets [N4][N5].
• In April 2025, the stock surged following improved earnings and record revenues for 2024 [N8].
• The company has raised capital through multiple equity offerings in 2025 and 2026 to fund operations and development [S1].

The company has demonstrated clinical validation of its CyPath® Lung test with strong sensitivity and specificity for early-stage lung cancer detection, addressing a critical need to improve diagnostic accuracy and reduce invasive procedures. Its ongoing large-scale clinical trial and collaborations with respected medical centers support potential broader adoption. The expansion into companion diagnostics for asthma and COPD and novel therapeutic research could diversify revenue streams. Maintaining CAP accreditation and operating its own laboratory supports quality and operational control. Recent capital raises provide funding to support development and commercialization efforts.

The company operates at a net loss with limited revenue and relies heavily on capital raises to fund operations, raising concerns about financial sustainability. It faces regulatory and commercialization challenges, including the need for FDA and international approvals. The Nasdaq delisting notice due to share price issues may impact investor confidence and liquidity. The clinical and commercial success of its diagnostic and therapeutic products is uncertain, and the company is in preliminary phases of product development. Competition in lung cancer diagnostics and companion diagnostics is significant, and failure to achieve profitability could impair operations.

bioAffinity's moat derives from its proprietary flow cytometry and AI-based diagnostic platform, CyPath® Lung, which addresses a significant unmet need for noninvasive early detection of lung cancer with clinical validation demonstrating high sensitivity and specificity. The company's ownership of a CAP-accredited and CLIA-certified laboratory (PPLS) supports test commercialization and quality control. Its ongoing large-scale clinical trial and collaborations with military and VA medical centers provide clinical validation and potential adoption pathways. The platform's extension into companion diagnostics for asthma and COPD and novel therapeutic research may broaden its product portfolio. However, the moat is challenged by the need for regulatory approvals, capital for commercialization, and competition in the diagnostic space.

• Capital and Liquidity Risk: The company has a history of net losses and relies on raising additional capital to fund operations. As of June 30, 2026, cash on hand was approximately $2.4 million with substantial doubt about continuing as a going concern beyond August 2026 without further financing [S2].
• Regulatory and Commercialization Risk: The company must obtain regulatory approvals for its diagnostic and therapeutic products, including potential FDA clearance and CE marking, and successfully commercialize these products to generate sustainable revenue [S1][S2].
• Nasdaq Listing Risk: The company received a Nasdaq delisting notice in July 2026 due to failure to maintain minimum bid price requirements and has appealed. Failure to regain compliance could lead to delisting with adverse consequences for liquidity and investor confidence [S2].
• Operational and Market Risks: The company faces risks related to competition in the diagnostic and therapeutic markets, uncertainties in clinical trial outcomes, and the ability to scale laboratory operations effectively [S1][S2].

• bioAffinity Technologies, Inc. develops noninvasive diagnostic laboratory tests for early-stage lung cancer and other lung diseases using flow cytometry combined with AI-based automated analysis [S1].
• Its first commercial diagnostic test, CyPath® Lung, detects cancer and cancer-related cells in sputum to identify lung malignancies, with clinical trial results showing 92% sensitivity and 87% specificity for nodules under 20 mm [S1].
• CyPath® Lung is performed by its wholly owned subsidiary PPLS, a CAP-accredited and CLIA-certified clinical laboratory with over 18 years of operation [S1].
• The company is advancing companion diagnostic tests for asthma and COPD to guide personalized treatment by detecting inflammation and drug receptor presence in sputum [S1].
• Research on novel cancer therapeutics targeting cancer cells selectively is ongoing, with plans for strategic partnerships [S1].
• A large-scale clinical trial (NCT07168993) began enrollment in March 2026 to evaluate CyPath® Lung's clinical performance in high-risk patients with indeterminate pulmonary nodules, involving multiple military and VA medical centers [S1].
• The company maintains CAP accreditation for its laboratory services, indicating adherence to high quality and safety standards [S1].
• Recent financials as of June 30, 2026, show cash and equivalents of $2.43 million, current assets of $3.87 million, current liabilities of $2.68 million, a current ratio of 1.44, and a cash ratio of 0.91 [S2].
• For the six months ended June 30, 2026, the company reported a net loss of approximately $3.37 million and basic and diluted EPS of -$0.64 [S2].
• Revenue was approximately $2.9 million for the six months ended June 30, 2026, and $6.2 million for the year ended December 31, 2025 [S2].
• The company has raised capital through multiple equity offerings in 2025 and 2026 to fund operations and development [S1].
• The company received a Nasdaq delisting notice in July 2026 due to failure to maintain minimum bid price requirements and has appealed [S2].
• Recent news highlights include the launch of a large-scale lung cancer study in March 2026, continued strength in CyPath Lung test sales, and stock price volatility related to earnings and revenue reports [N1][N2][N3][N4][N5][N7][N8].